Table 5 Correlations between baseline biomarkers vs baseline and longitudinal change in DAT specific binding ratios among LRRK2 G2019S carriers.

From: Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

 

Correlation with baseline mean striatum SBR

Correlation with 2-year percent change from baseline in mean striatum SBR

Baseline Biomarker

N Obs

Spearman’s Rho

p value

N Obs

Spearman’s Rho

p value

Polygenic risk score

155

−0.10

0.2304

115

0.03

0.7513

Serum urate

140

0.02

0.8513

101

−0.01

0.8880

CSF Abeta (quintile)

143

−0.06

0.4876

105

0.13

0.2016

CSF tau (quintile)

143

0.02

0.7903

105

0.15

0.1296

CSF p-tau (quintile)

143

0.07

0.3942

105

0.14

0.1511

Serum NfL

135

0.13

0.1342

114

−0.03

0.7724

Urine total di-18:1-BMP

164

−0.15

0.0523

119

−0.06

0.5067

Urine total di-22:6-BMP

164

−0.28

0.0003*

119

-0.03

0.7298

Urine 2,2-di-22:6-BMP

164

−0.27

0.0005*

119

−0.04

0.6932

  1. Correlation coefficients and p values were computed using Spearman partial rank-order correlations controlling for age and sex (correlations with polygenic risk score also controlled for the first five principal components of the genetic data; correlations with 2-year change in DAT also controlled for mean striatum SBR at baseline).
  2. DAT dopamine transporter. SBR specific binding ratio. CSF cerebrospinal fluid. NfL neurofilament light chain. BMP bis(monoacylglycerol)phosphate. *Significance level for comparisons is p < 0.0056 (after Bonferroni correction).
Back to article page